Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis

Article Abstract:

Long-term treatment with cyclophosphamide may increase the risk of inflammation and cancer of the bladder in people with Wegener granulomatosis. Cyclophosphamide is often used to treat Wegener granulomatosis, which involves the inflammation of blood vessels and the death of tissue. A total of 145 people who took cyclophosphamide for Wegener granulomatosis were followed for 0.5 to 27 years. Of these people, 73 (50%) had blood in their urine primarily caused by bladder inflammation. Among 60 of these people, 42 (70%) appeared to have an bladder injury caused by cyclophosphamide, based on examination of their bladders. Seven (5%) of the people receiving cyclophosphamide developed bladder cancer. Most of these people with cancer previously had blood in their urine and had taken more than a total of 100 milligrams of cyclophosphamide. Statistical analysis suggested that blood in the urine was associated with an increased risk for bladder cancer among this population.

Author: Linehan, W. Marston, Fauci, Anthony S., Hoffman, Gary S., Walther, McClellan M., Sneller, Michael C., Talar-Williams, Cheryl, Hijazi, Yasmine M., Hallahan, Claire W., Lubensky, Irina, Kerr, Gail S.
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1996
Risk factors, Drug therapy, Bladder cancer, Cystitis, Wegener's granulomatosis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Use of testosterone to prevent cyclophosphamide-induced azoospermia

Article Abstract:

The addition of testosterone therapy to treatment with cyclophosphamide chemotherapy may protect male patients' long-term fertility. Testosterone was added to five of 15 male patients' cyclophosphamide chemotherapy and sperm counts were done before, during, and six months after eight months of treatment. All patients had a zero sperm count during treatment. Sperm counts returned to normal levels six months after treatment among all patients taking additional testosterone. Only one of 10 patients' sperm counts returned to normal among the patients not taking testosterone.

Author: Bartoli, Ettore, Masala, Antonio, Faedda, Rossana, Alagna, Sergio, Satta, Andrea, Chiarelli, Giorgio, Rovasio, Pier Paolo, Ivaldi, Riccardo, Taras, Marianna Simona, Lai, Elisabetta
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1997
Health aspects, Care and treatment, Testosterone, Spermatogenesis, Infertility, Male, Male infertility

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: Complications and side effects, Cyclophosphamide
Similar abstracts:
  • Abstracts: Volunteerism: the gift of hope. Urban dentistry: challenges and rewards. A life in science: Dr. Genco receives gold medal for research
  • Abstracts: Positron emission tomography in the study of brain metabolism in psychiatric and neuropsychiatric disorders. Structure and function in neurology and psychiatry
  • Abstracts: Common solid tumors of childhood. Common musculoskeletal tumors of childhood and adolescence. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors
  • Abstracts: Transmission of infectious diseases in outpatient health care settings. Infectious diseases and injuries in child day care: opportunities for healthier children
  • Abstracts: Clinical and microbiologic features of urethritis in men in Toulouse, France. Haemophilus parainfluenzae causing sexually transmitted urethritis: report of a case and evidence for a beta-lactamase plasmid mobilizable to Escherichia coli by an Inc-W plasmid
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2026 Advameg, Inc.